Now showing items 1-1 of 1

    • Thumbnail

      In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study 

      Quindós Andrés, Guillermo; Miranda Cadena, Katherine; San Millán Gutiérrez, Rosario María ORCID; Borroto Esoda, Katyna; Cantón, Emilia; Linares Sicilia, María José; Hamprecht, Axel Georg; Montesinos, Isabel; Tortorano, Anna Maria; Prigitano, Anna; Vidal García, Matxalen ORCID; Marcos Arias, Cristina; Guridi Cortaberria, Andrea ORCID; Sánchez Reus, Ferrán; Machuca Bárcena, Jesús; Rodríguez Iglesias, Manuel Antonio; Martín Mazuelos, Estrella; Castro Méndez, Carmen; López Soria, Leyre; Ruiz Gaitán, Alba; Fernández Rivero, Marcelo; Lorenzo, Damaris; Capilla, Javier; Rezusta, Antonio; Pemán, Javier; Guarro, Josep; Pereira, Joana; Célia, Pais; Romeo, Orazio; Ezpeleta Lobato, Guillermo; Jauregizar Albonigamayor, Nerea ORCID; Angulo, David; Eraso Barrio, María Elena ORCID (Frontiers Media, 2022-05)
      BackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. ObjectiveThe aim of this study was to assess the in ...